Skip to main content
Premium Trial:

Request an Annual Quote

SQI to Raise Up to $4.9M in Private Placement

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – SQI Diagnostics today announced it plans to raise up to C$5 million ($4.9 million) through a non-brokered private placement.

The company plans to use net proceeds to fund its development and commercialization programs and for general working capital, it said in a statement. Among SQI's technologies is its SQiDworks Diagnostics fully automated fluidics workstation for use with its proprietary QuantiSpot microarray test. It also has a number of diagnostic panels for autoimmune diseases either available or under development.

Toronto-based SQI plans to offer up to 2 million units. Each unit, which is being priced at C$2.50, includes one share of the company's stock and a purchase warrant for half a share of common stock.

Each whole common share purchase warrant allows the holder to acquire one common share for C$5 for a two-year period starting from the date of issuance.

Closing of the placement will be on or about Aug. 12.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more